COPENHAGEN, Denmark, March 12, 2026 (GLOBE NEWSWIRE) -- Cbio A/S today announced that it has received regulatory clearance to begin a first-in-human Phase I/IIa clinical trial of novoleucel, the ...

The breakthrough, published Tuesday in the journal Cell, offers a promising new strategy to combat relapse, which occurs in more than half of patients following CAR-T therapy. The approach works by ...

Following the appointment of a new leadership team on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to move TVGN 489 into its next clinical phase. The company is ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDTCompany ParticipantsBassil Dahiyat - Co-Founder, ...

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026Zipalertinib rolling NDA ...

MiNK Therapeutics (NASDAQ:INKT) shares climbed about 80% on Tuesday after the company revealed a collaboration with C-Further ...

The partnership draws on clinical experience from over 100 transplant patients treated with tegoprubart.

Soligenix (NASDAQ: SNGX) announced that SGX945 (dusquetide) has received Promising Innovative Medicine (“PIM”) designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the ...

With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.

As a world leader in the immuno-oncology field, Dr. Zihai Li has long been at the forefront of cancer immunotherapy.

On February 26, 2026, Johnson & Johnson (NYSE:JNJ) provided an update, reporting promising Phase 1b data for pasritamig, a ...